MedTrace Logo

Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component

NCT00680732 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1370

Last updated 2010-09-14

No results posted yet for this study

Summary

Our objective was to investigate the importance of malaria infection/disease during pregnancy and more particularly during the first trimester; we also looked at the maternal-foetal interactions and their influence on the subsequent child's response to malaria infections during the first year of life. This study was carried out !in the same population recruited for the IUGR study (NCT00642408).

Conditions

Interventions

DIETARY_SUPPLEMENT

Multiple micronutrients supplements (MMS)

Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg

DIETARY_SUPPLEMENT

Iron and folic acid (IFA)

Iron 60 mg and folic acid 400 mcg

DRUG

Chloroquine (CQ)

Tablets 100 mg of chloroquine base

DRUG

Sulphadoxyne-pyrimethamine (SP)

Tablets

Sponsors & Collaborators

  • Departments of Parasitology and Public Health, ITM, Antwerp, Belgium

    collaborator UNKNOWN

  • Centre Muraz

    collaborator OTHER

  • Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso

    collaborator UNKNOWN

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Marie Claire Henry, MD · Centre Muraz

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
15 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • Burkina Faso

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00680732 on ClinicalTrials.gov